In fact, this entire PSU rally that we have seen for almost now about six months or so, it has been quite surprising for a lot of us. Though we might feel that because of the sheer price move that has happened, all the valuations are looking stretched.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the